Roche Backs Out Of Kosan Epothilone Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
Kosan is “actively seeking” a new partner to begin Phase II trial for KOS-1584 after Roche unexpectedly terminates five-year collaboration.
You may also be interested in...
Kosan Buy Puts BMS Front And Center In HSP90 Race, Strengthens Epothilone Position
BMS gains several clinical-stage oncology programs with agreement to acquire Kosan for $190 million.
Kosan Buy Puts BMS Front And Center In HSP90 Race, Strengthens Epothilone Position
BMS gains several clinical-stage oncology programs with agreement to acquire Kosan for $190 million.
Roche Global Head Of Pharma Partnering Dan Zabrowski: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)
Swiss firm’s R&D alliances comprise more than 80 deals in 20 countries.